Category: Markets
Published: 2026-06-22T14:48:00.000Z
Piper Sandler has reiterated an Overweight rating and a $115.00 price target for Abbott Laboratories (NYSE:ABT), anticipating accelerating growth in fiscal year 2027 with top-line growth above 7% and double-digit adjusted EPS growth. Despite the stock trading near its 52-week low and being down 28.6% year-to-date, InvestingPro analysis suggests it is undervalued. The firm's positive outlook follows discussions with Abbott's leadership regarding continuous glucose monitoring, electrophysiology, the Exact Sciences deal, nutrition, and diagnostics comparisons.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.